G1 Therapeutics Inc (GTHX)

$3.98 0.12 (3.11%)

13:14 EDT GTHX Stock Quote Delayed 30 Minutes

Why Is G1 Therapeutics (GTHX) Stock Down 45% Today?

By William White, InvestorPlace Writer Feb 13, 2024

G1 Therapeutics stock is down on Tuesday after the company provided GTHX investors with an update on a Phase 3 clinical trial.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Why Is G1 Therapeutics (GTHX) Stock Down 52% Today?

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

More Articles

Volume:

Previous Close -

Market Cap 169.97M

PE Ratio -4.19

EPS -0.95

Volume (Avg. Vol.) 250,760

Day's Range $3.84 - $4.05

52-Week Range $1.08 - $5.00

Dividend & Yield N/A (N/A)

GTHX Stock Predictions, Articles, and G1 Therapeutics Inc News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Nov 18, 2022

It's time to start closing out the trading week with a dive into the biggest pre-market stock movers for Friday morning!

7 Great Biotech Stocks to Buy and Hold Now

By Chris Markoch, InvestorPlace Contributor Jun 11, 2020

As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.

G1 Therapeutics stock sinks 53% in wake of study update (NASDAQ:GTHX)

From Seeking Alpha Feb 13, 2024

G1 Therapeutics (GTHX) stock sank 53% Tuesday, the day after the company issued an update for a Phase 3 study of its breast cancer drug trilaciclib. Read more here.

G1 Therapeutics stock dives 36% post-market on P3 study update (NASDAQ:GTHX)

From Seeking Alpha Feb 12, 2024

Shares of G1 Therapeutics (GTHX) plunged 36% in post-market trading after the company said the independent data monitoring committee overseeing a pivotal Phase

G1 Therapeutics stock falls as JPMorgan downgrades

From Seeking Alpha Oct 6, 2023

JPMorgan downgraded G1 Therapeutics (GTHX) on Friday citing a potential sales miss for its lead product, Cosela in Q3. Read more here.

G1 Therapeutics trilaciclib reduces safety issues linked to Trodelvy

From Seeking Alpha May 10, 2023

G1 Therapeutics (GTHX) said data from a phase 2 trial showed benefit of trilaciclib in reducing adverse events related to Gilead's (GILD) Trodelvy. Read more here

H.C. Wainwright Sticks to Its Buy Rating for G1 Therapeutics (GTHX)

From TipRanks Dec 8, 2022

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on G1 Therapeutics (GTHX – Research Report), with a price tar...

Needham Remains a Buy on G1 Therapeutics (GTHX)

From TipRanks Dec 8, 2022

Needham analyst Gil Blum maintained a Buy rating on G1 Therapeutics (GTHX – Research Report) today and set a price target of $32.00. The company’s ...

ADVERTISEMENT